⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
LABT News
Lakewood-Amedex Biotherapeutics Inc. Common Stock
Lakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot Ulcers
prnewswire.com
LABT
Lakewood-Amedex Biotherapeutics Announces Positive Data for the Advancement of Lead Candidate, Nu-3, in Infected Diabetic Foot Ulcers
prnewswire.com
LABT
Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for Phase 2 Clinical Trial of Nu-3
prnewswire.com
LABT
Lakewood-Amedex Biotherapeutics Announces Positive Antimicrobial Resistance Data for Lead Candidate Targeting Infected Diabetic Foot Ulcers
prnewswire.com
LABT
Form 8-K
sec.gov
LABT
ENVB
PFE
Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors
prnewswire.com
ENVB
LABT
Lakewood-Amedex Biotherapeutics Announces Direct Listing on Nasdaq; Shares Trading Under the Symbol "LABT"
prnewswire.com
LABT